Description: Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company provides its products for various medical indications comprising glaucoma, migraine, antibiotic, anesthetic, endometriosis, irritable bowel syndrome, obesity, congestive heart failure, antipsychotic, pain management, thyroid deficiency, dryness of the mouth, epilepsy, gout, bronchospasms, hypertension, and gallstone. Lannett Company, Inc. markets its products under the Diamox, Fioricet, Fiorinal, Fiorinal w/ Codeine #3, Cleocin, Danocrine, Bentyl, Tenuate, Dospan, Lanoxin, Adoxa, Periostat, Prolixin, Dilaudid, Levoxyl, Synthroid, Loxitane, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Dyazide, and Actigall brands. It also manufactures active pharmaceutical ingredients. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. It has development and supply agreements with Azad Pharma AG, Swiss Caps of Switzerland, Pharma 2B, and the GC Group of Israel, as well as with Jerome Stevens Pharmaceuticals, Inc., Cerovene, and Summit Bioscience LLC. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.
Home Page: www.lannett.com
LCI Technical Analysis
1150 Northbrook Drive
Trevose,
PA
19053
United States
Phone:
215 333 9000
Officers
| Name | Title |
|---|---|
| Mr. Timothy C. Crew | CEO & Director |
| Mr. John Kozlowski | VP of Fin., CFO & Principal Accounting Officer |
| Mr. John M. Abt | VP and Chief Quality, Information Technology & Operations Officer |
| Mr. Samuel H. Israel | Gen. Counsel & Chief Legal Officer |
| Ms. Maureen M. Cavanaugh | Sr. VP & Chief Commercial Operations Officer |
| Ms. Kristie Stephens | Chief Compliance Officer & VP of Regulatory Affairs |
| Mr. Grant Brock | VP of Operations |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 16.3934 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8385 |
| Price-to-Sales TTM: | 0.0834 |
| IPO Date: | 1997-01-02 |
| Fiscal Year End: | June |
| Full Time Employees: | 564 |